Barely Significant
← all excerpts

<i>PPARA</i> Polymorphism Influences the Cardiovascular Benefit of Fenofibrate in Type 2 Diabetes: Findings From ACCORD-Lipid.

Diabetes · 2020 · PMC7085251 · PMID 31974142

Europe PMCDOI
2
hedged sentences
0.0700
closest p · 1.4× alpha
0.0700
boldest claim

The sentences

approached significanceP = 7 × 10 −2so close (0.05 < p ≤ 0.1)
The association also approached significance in liver ( P = 7 × 10 −2 ) despite the smaller sample size.

also in 8,237 other papers

nominally significantno p-value reported
rs6008845 Effect on Lipid and Chemokine Response to Fenofibrate As shown in Table 3 , the larger cardiovascular benefit of fenofibrate among T/T homozygotes was not paralleled by differences in clinical characteristics at baseline, the only nominally significant difference being in the age of onset of diabetes.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.